featuring the CEOs of the leading international and domestic pharmaceutical companies, who will share their insights and perspectives on the major short and long-term concernsthey have for their business

Biosimilars are ready to make a breakthrough on the global and local pharmaceutical market. However, developing a follow-on biological product is an altogether more complicated process than producing standard generic drugs.
The session will take a close look at how the Russian biosimilars market is likely to develop, and will examine how it might affect the market in the next 3-5 years.

featuring trusted sector experts, who will present a detailed statistical review of the key market segments, therapy areas, products and companies, as well as evaluating the key drivers and barriers to future market development.

Day on Regulatory Affairs and Compliance
Topics to be discussed:
• Product Approval and Registration: Is the new system an improvement on the old one? What major challenges are companies currently facing?
• Clinical Trials: What are the main authorities’ reasons for conducting local trials, and how do they affect the time to market? 
• Harmonisation and Regulatory Framework Development: Development of the Customs Union
• Quality Assurance, Pharmacovigilance and Compliance: What are the main challenges in establishing and managing a QA management system in Russia?

Day on Achieving Commercial Excellence in the Pharmaceutical Market

Topics to be discussed:
• What is the role of effective product portfolio and life-cycle management in enhancing profits and addressing a company’s business challenges?
• What are the opportunities for sustaining revenue streams via Rx-to-OTC switch?
• How to effectively measure your sales team’s efficiency and qualify sizing decisions?
• What can Russia learn from the companies working in the market that are restricting their interaction with healthcare professionals?
• Assessing the importance of channel mix variations – the role of which promotional channels are expected to increase in the short term?

Development of the healthcare system’s financing mechanism: possible schemes and scenarios. Is Russia really different from other European countries in its approach to healthcare funding? The session will gather together
international and local experts on health economics to discuss how to balance both the healthcare system budgetary considerations and the market access reality.

focusing on key aspects of pharmaceutical industry development, giving you the unique opportunity to share ideas and network over breakfast!